The US Food and Drug Administration (FDA) has granted fast track designation to Alvine Pharmaceuticals' ALV003 for the potential treatment of celiac disease. Alvine is at present conducting Phase 2 trials with ALV003, an orally ...
Tags: ALV003, treatment of celiac disease, orally administered mixture